On January 30, 2018, the Government of Canada posted the Comprehensive and Progressive Partnership for Trans-Pacific Partnership (CPTPP) - Backgrounder. According to the Backgrounder, Canada and other signatories agreed to suspend certain obligations under the Trans-Pacific Partnership (TPP) with respect to intellectual property, patents and pharmaceuticals, including on patent term adjustments to compensate for unreasonable patent office delays and marketing authorization delays. Canada already provides for patent term extension for marketing authorization delays under the Patent Act and Certificate of Supplementary Protection Regulations which came into force September 21, 2017 (as previously reported). On February 20, 2018, Global Affairs Canada subsequently issued a news release announcing the release of the full text of the CPTPP and projected economic impacts of the CPTPP on Canada.
Related Publications & Articles
-
Health Canada releases notice on aligned reviews between Health Canada and health technology assessment organizations
On November 5, 2024, Health Canada released the Notice to industry: Aligned reviews between Health Canada and health technology assessment organizations.Read More -
Health Canada posts 2023 to 2024 review on drug shortages
On November 20, 2024, Health Canada posted Drug shortages in Canada: Fiscal year 2023 to 2024 in review.Read More -
Agile licensing amendments registered
Following consultation starting in 2022, on November 29, 2024, Regulations Amending Certain Regulations Made Under the Food and Drugs Act (Agile Licensing) were registered.Read More